Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months.
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Heart failure; Hypertension
- Focus Biomarker; Therapeutic Use
- Acronyms CAN-DHF
- Sponsors Takeda Pharma
- 10 Jun 2017 Biomarkers information updated
- 06 Oct 2012 Planned number of patients changed from 300 to 350.
- 10 Feb 2009 Actual patient numbers (22) added as reported by ClinicalTrials.gov.